UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    18

    UCB Unleashes the Power of Data in New Collaboration

    UCB and Stanford Medicine have established a multi-year collaboration to enhance patient value for people living with severe diseases.

    Read More Share:linkedin| twitter| email

    Nov

    17

    UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

    Read More Share:linkedin| twitter| email

    Nov

    05

    UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)